| Article ID | Journal | Published Year | Pages | File Type | 
|---|---|---|---|---|
| 1376072 | Bioorganic & Medicinal Chemistry Letters | 2007 | 4 Pages | 
Abstract
												A novel neurokinin-1 receptor antagonist, (±)-(1R∗,3S∗,4S∗,5S∗)-4-[(N-(2-methoxy-5-trifluoromethoxybenzyl)amino]-3-phenyl-2-aza-7-oxabicyclo[3.3.0]octane (1), was synthesized stereoselectively using Padwa’s intramolecular 1,3-dipolar cycloaddition methodology as the key step. Compound (±)-1 showed high affinity for the NK-1 receptors in human IM-9 cells with an IC50 value of 0.22 nM. This new structural scaffold demonstrated significant in vivo antagonistic activity in the guinea pig ureter capsaicin-induced plasma extravasation model with an ED50 value of 1–10 mg/kg, po.
Graphical abstractFigure optionsDownload full-size imageDownload as PowerPoint slide
Related Topics
												
													Physical Sciences and Engineering
													Chemistry
													Organic Chemistry
												
											Authors
												Yuji Shishido, Fumitaka Ito, Hiromasa Morita, Masaya Ikunaka, 
											![First Page Preview: Stereoselective synthesis of a novel 2-aza-7-oxabicyclo[3.3.0]octane as neurokinin-1 receptor antagonist Stereoselective synthesis of a novel 2-aza-7-oxabicyclo[3.3.0]octane as neurokinin-1 receptor antagonist](/preview/png/1376072.png)